Printer Friendly

CYGNUS REACHES SETTLEMENT WITH ELAN OVER NICOTINE PATCH SUIT

 REDWOOD CITY, Calif., April 29 /PRNewswire/ -- Cygnus Therapeutic Systems (NASDAQ: CYGN) and Elan Transdermal Ltd., Elan Corp. plc, announced that an amicable settlement had been reached by the parties regarding a lawsuit brought by Elan Transdermal and Elan against Cygnus alleging patent infringement by the manufacture and sale of nicotine patches manufactured by Cygnus, Cygnus said today. Cygnus indicated that the settlement would have no material adverse financial impact upon it.
 Cygnus, located in Redwood City, is an innovative developer of transdermal and other drug delivery systems. In addition to Nicotrol(R), marketed by Warner Lambert, Cygnus has two products in advanced clinical trials. One is an estradiol patch to treat menopausal symptoms, with a proprietary seven-day Lastomeric(TM) design, more cost- effective, comfortable and convenient than the 3-1/2-day patches presently available. A 24-hour fentanyl patch for postoperative pain management is also in Phase III clinical testing.
 The company has more than a dozen products in earlier stages of development. These include eight female hormone replacement therapy patches that use proprietary seven-day technology for improved comfort, convenience and cost-effectiveness. Two prototype products for oral hygiene are in consumer evaluation. Transdermal systems for treatment of angina, anxiety, benign prostatic hypertrophy and chemotherapy- related nausea are also in the development pipeline.
 -0- 4/29/93
 /CONTACT: Shirley Clayton of Cygnus, 415-369-4300/
 (CYGN)


CO: Cygnus Therapeutic Systems; Elan Transdermal Ltd.; Elan Corp. plc ST: California IN: MTC SU:

GT-SG -- SJ003 -- 2696 04/29/93 13:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1993
Words:245
Previous Article:NEW VISA TV ADS FEATURING ANHEUSER-BUSCH THEME PARKS, U.S. OPEN TENNIS TOURNAMENT TO BOOST SUMMER TRAVEL
Next Article:AETNA TO EXPAND ATLANTA HEALTH CARE SERVICES
Topics:


Related Articles
ELAN: COURT REFUSES TO CONTINUE RESTRAINT AGAINST MARION MERRELL DOW
ELAN STEPS UP PROSTEP PATCH PRODUCTION FOR CYANAMID'S LEDERLE; MORE THAN FOUR MILLION SHIPPED THUS FAR
ALZA, CYANAMID, ELAN AND MARION MERRELL CONCLUDE AGREEMENTS AND REACH AN OUT-OF-COURT SETTLEMENT
COURT RULES IN FAVOR OF CYGNUS MOTION FOR SUMMARY JUDGMENT; DISMISSES IMPORTANT PARTS OF PATENT INFRINGEMENT SUIT
CYGNUS SHIPS ITS NICOTINE PATCH
ELAN CONFIDANT OF SUCCESSFUL CONCLUSION TO PATENT INFRINGEMENT CASE
USE OF ELAN'S PATCH DOUBLES QUIT RATE AT ONE YEAR
CYGNUS 'WAKING HOURS' NICOTINE PATCH SHOWS IMPRESSIVE RESULTS IN A RECENT STUDY
COURT RULES IN FAVOR OF ALZA & MARION MERRELL DOW, DECLARES CIBA-GEIGY NICOTINE PATENT INVALID
HOECHST MARION ROUSSEL, ALZA CORPORATION AND CIBA-GEIGY SETTLE NICOTINE PATCH PATENT LITIGATION

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters